DI SERAFINO, LUIGI
 Distribuzione geografica
Continente #
NA - Nord America 1.118
EU - Europa 636
AS - Asia 490
AF - Africa 30
SA - Sud America 2
Totale 2.276
Nazione #
US - Stati Uniti d'America 1.088
SG - Singapore 287
IT - Italia 264
CN - Cina 172
NL - Olanda 128
FI - Finlandia 84
UA - Ucraina 38
IE - Irlanda 34
DE - Germania 32
CA - Canada 30
CI - Costa d'Avorio 26
GB - Regno Unito 18
RU - Federazione Russa 17
VN - Vietnam 13
IN - India 6
CZ - Repubblica Ceca 5
FR - Francia 5
BG - Bulgaria 4
KE - Kenya 4
BE - Belgio 3
IR - Iran 3
JP - Giappone 3
KZ - Kazakistan 2
SE - Svezia 2
BD - Bangladesh 1
BR - Brasile 1
ES - Italia 1
HK - Hong Kong 1
JO - Giordania 1
LT - Lituania 1
PE - Perù 1
TW - Taiwan 1
Totale 2.276
Città #
Singapore 241
Chandler 143
Amsterdam 123
Naples 91
Santa Clara 89
Ashburn 84
Millbury 78
Princeton 64
Nanjing 58
Boston 55
Des Moines 35
Ottawa 29
Wilmington 24
Jacksonville 23
Lappeenranta 18
Nanchang 17
Lawrence 15
Beijing 14
Jiaxing 13
Dong Ket 12
Shenyang 12
Hebei 11
Napoli 11
Tianjin 11
Helsinki 10
Washington 10
Milan 8
Montecchio Emilia 8
Fairfield 7
Norwalk 7
Torre del Greco 7
Council Bluffs 6
Augusta 5
Boardman 5
Brno 5
Dallas 5
Florence 4
Kunming 4
Moscow 4
Nairobi 4
Pune 4
Redwood City 4
San Giuseppe Vesuviano 4
San Mateo 4
Sofia 4
Berlin 3
Chengdu 3
Genoa 3
Kronberg 3
Taurianova 3
Trecase 3
Villaricca 3
Volla 3
Almaty 2
Ann Arbor 2
Ardabil 2
Brussels 2
Casavatore 2
Changsha 2
Chongqing 2
Eboli 2
Giugliano in Campania 2
Hangzhou 2
Lanzhou 2
Orta di Atella 2
Osaka 2
Portici 2
Pozzuoli 2
Qingdao 2
Rayleigh 2
Redmond 2
Salerno 2
Scuola 2
Seattle 2
The Dalles 2
Vicenza 2
West Jordan 2
Amman 1
Aurisina Cave 1
Avellino 1
Aversa 1
Baranzate 1
Beveren 1
Bologna 1
Cambridge 1
Casalnuovo Di Napoli 1
Casoria 1
Cerreto Guidi 1
Dhaka 1
Dublin 1
Eindhoven 1
Falkenstein 1
Falls Church 1
Fremont 1
Grumo Nevano 1
Guangzhou 1
Hong Kong 1
Houston 1
Ivano-Frankivsk 1
Jinan 1
Totale 1.485
Nome #
LA TRANSATTIVAZIONE Gβγ-DIPENDENTE DEL RECETTORE DELL’EGF E’ MEDIATA DAL RECETTORE DELL’UROTENSINA II 68
ADDED Index or percentage diameter of residual coronary stenosis to risk-stratify patients presenting with STEMI 52
ATHERECTOMY AS ALTERNATIVE ENDOVASCULAR THERAPY FOR INFRAINGUINAL ARTERY DISEASE. 47
True double bifurcation lesions: new application of the self-expandable Axxess stent and review of literature with dedicated bifurcation devices 46
Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry 43
Effects of Successful Percutaneous Lower Extremity Revascularization on Cardiovascular Outcome in Patients with Peripheral Arterial Disease 42
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 39
Extent of cardiac damage and mortality in patients undergoing transcatheter aortic valve implantation 39
Predictors of adherence to composite therapy after acute coronary syndromes 37
Antiplatelet therapy in acute coronary syndromes. Lights and shadows of platelet function tests to guide the best therapeutic approach 36
Vantaggi del trattamento endoprotesico degli aneurismi aortici in categorie ad alto rischio chirurgico. 36
Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel 35
C-flip, A protein Required For Embryonic Heart Development, is markedly increased in pressure overload myocardial hypertrophy 34
ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. 34
Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. 34
Response to letter regarding article, "revascularization decisions in patients with stable angina and intermediate lesions: Results of the international survey on interventional strategy" 34
Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI 34
Vantaggi del trattamento endoprotesico degli aneurismi aortici in categorie ad alto rischio chirurgico 34
Low-dose quinacrine reduces vascular restenosis without affecting re-endothelialization 34
L’IMPIANTO DI STENT NELLE ARTERIE DEGLI ARTI INFERIORI RIDUCE IL RISCHIO CARDIOVASCOLARE IN PAZIENTI CON ATEROSCLEROSI PLURIDISTRETTUALE. 33
Very late bioresorbable scaffold thrombosis and reoccurrence of dissection two years later chronic total occlusion recanalization of the left anterior descending artery 33
Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: The FAVOR II Europe-Japan study 33
Endovascular repair for isolated iliac artery aneurysms: case report and review of the current literature. 32
FFR prediction model based on conventional quantitative coronary angiography and the amount of myocardium subtended by an intermediate coronary artery stenosis 32
L’Urotensina II svolge un ruolo protettivo nel rimodellamento post-ischemico e nella transizione verso lo scompenso cardiaco congestizio 31
Il ruolo dell’Urotensina II nel rimodellamento post-ischemico e nella transizione verso lo scompenso cardiaco congestizio 30
Induction of mitogen activated protein kinases in response to pressure overload: a novel possible biomarker for uncontrolled human hypertension. 30
Comparison of the Effect of Dual-Axis Rotational Coronary Angiography Versus Conventional Coronary Angiography on Frequency of Acute Kidney Injury, X-Ray Exposure Time, and Quantity of Contrast Medium Injected 30
Histamine release, after peripheral ischemia, induce inteleukin 16 (II-16) expression and regulate collateral vessel development in mice. 29
The role of fractional flow reserve to guide stent implantation. 29
How would I treat? The invited expert's opinion 29
AngioJet rheolytic thrombectomy for acute superficial femoral artery stent or femoropopliteal by-pass thrombosis 29
Ruolo del derivato acridinico Quinacrina nella prevenzione della restenosi e della trombosi intrastent. 28
SAFETY AND EFFICACY OF OUBACK CATHETER-ASSISTED SUBINTIMAL RECANALIZATION OF TOTAL CHRONIC ILIAC ARTERY OCCLUSION. 28
Quinacrine as a novel drug in the prevention of in-stent restenosis and thrombosis. 28
Quinacrine as a Novel Anti-Restenotic and Anti-Thrombotic Drug for Coronary Artery Interventions. 28
Coronary microcirculation and peri-procedural myocardial injury during elective percutaneous coronary intervention 28
L’ipertrofia miocardia da sovraccarico pressorio induce un notevole incremento dell’espressione di C-Flip, una proteina indispensabile per lo sviluppo embrionale del cuore 27
Gβγ-dependent transactivation of the epidermal growth factor receptor by the Urotensin-II receptor. 27
Prevenzione della restenosi e della trombosi intrastent: ruolo del derivato acridinico quinacrina 27
Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry 27
Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial 27
Myocardial mass affects diagnostic performance of non-hyperemic pressure-derived indexes in the assessment of coronary stenosis 26
Ruolo dell’UII nello sviluppo dell’ipertrofia cardiaca in vivo e nella transizione verso lo scompenso cardiaco congestizio. 26
Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. 25
Stent implantation in the arteries of the lower limbs reduces cardiovascular risk in peripheral arterial disease. 24
Rotational atherectomy for the treatment of isolated femoral artery traumatic lesion: A case report 24
Ruolo dell’ UII nello sviluppo dell’ipertrofia cardiaca in vivo e nella transizione verso lo scompenso cardiaco congestizio 23
Effetti dell’Urotensina II sulle proliferazione delle fibrocellule muscolari lisce 23
Monocyte-platelets aggregates as cellular biomarker of endothelium-dependent coronary vasomotor dysfunction in patients with coronary artery disease. 23
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 22
Revascularization Decisions in Patients With Stable Angina and Intermediate Lesions: Results of the International Survey on Interventional Strategy. 22
Periprocedural Myocardial Injury and Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Interventions of Coronary Chronic Total Occlusion 22
Periprocedural myocardial infarction in patients undergoing complex versus noncomplex percutaneous coronary intervention 21
La ridotta risposta ipertrofica da sovraccarico pressorio si associa a dilatazione ventricolare sinistra e ridotto reclutamento di cellule T CD4+ CD8+ in un modello murino di diabete mellito tipo II 21
Ruolo dell’urotensina II (UII) nello sviluppo dell’ipertrofia cardiaca in vivo e nella transizione verso lo scompenso cardiaco congestizio 21
L’urotensina II svolge un ruolo protettivo nel rimodellamento post ischemico e nella transizione verso lo scompenso cardiaco congestizio 21
Double-kissing culotte technique for coronary bifurcation stenting 21
Impact of COVID-19 pandemic on timing and early clinical outcomes of transcatheter aortic valve implantation 20
Contemporary Evidence and Practice on Right Heart Catheterization in Patients with Acute or Chronic Heart Failure 20
RUOLO DEL DERIVATO ACRIDINICO QUINACRINA NELLA PREVENZIONE DELLA RESTENOSI E DELLA TROMBOSI INTRASTENT. 20
Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel 20
The age, creatinine, and ejection fraction score to risk stratify patients who underwent percutaneous coronary intervention of coronary chronic total occlusion. 20
Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. 20
Macrophage migration inhibitory factor (MIF) is associated with degree of collateralization in patients with totally occluded coronary arteries 20
Functionally complete coronary revascularisation in patients presenting with ST-elevation MI and multivessel coronary artery disease 19
Effects of urotensin II inhibition on smooth muscle cell proliferation and apoptosis 19
Transfemoral PTA of total subclavian occlusion anatomic definition prior stent implantation by Amicath rapid exchange catheter 19
Prognostic value of fractional?flow?reserve: linking physiologic severity to clinical outcomes. 19
Intracoronary EnalaPrilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study. 19
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 19
Management of Non-Culprit Lesions in STEMI Patients with Multivessel Disease 18
La ridotta risposta ipertrofica da sovraccarico pressorio si associa a dilatazione ventricolare sinistra e ridotto reclutamento di cellule T CD4+ CD8+ in un modello murino di diabete mellito tipo II 18
Long-term clinical outcome after fractional flow reserve- versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. 18
Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: comparison with fractional flow reserve. 18
Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. 18
Ruolo dell’Urotensina II nello sviluppo dell’ipertrofia cardiaca in vivo e nella transizione verso lo scompenso cardiaco congestizio 17
Relationship between peripheral arterial reactive hyperemia and the index of myocardial resistance in patients undergoing invasive coronary angiography 16
Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. 15
Impact of alpha- and Beta-adrenergic receptor blockers on fractional flow reserve and index of microvascular resistance. 15
Uric acid plasma levels are associated with C-reactive protein concentrations and the extent of coronary artery lesions in patients with acute coronary syndromes 14
In-stent fractional flow reserve variations and related optical coherence tomography findings: the FFR-OCT co-registration study 14
Response to letter to the editor regarding article "Macrophage migration inhibitory factor (MIF) is associated with degree of collateralization in patients with totally occluded coronary arteries" 14
Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry 13
Invasive functional assessment of coronary artery stenosis using fractional flow reserve 13
Impact of negative lesion characteristics of chronic total occlusions on procedural outcome and strategy. 13
Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. 13
Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond 12
Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry 12
Invasive Assessment of Coronary Microcirculation: A State-of-the-Art Review 10
Impact of biomarker type on periprocedural myocardial infarction in patients undergoing elective PCI 9
Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome 9
May FFR-guided PCI save lives?: Commentary on: “Clinical impact of FFR-guided PCI compared to angio-guided PCI from the France PCI registry” 8
Artificial Intelligence as a Tool for Diagnosis of Cardiac Amyloidosis: A Systematic Review 6
#FullPhysiology: a systematic step-by-step guide to implement intracoronary physiology in daily practice 6
A Comparison Between Radial Artery Compression Devices for Patent Hemostasis After Transradial Percutaneous Interventions 5
Potential additive effects of ticagrelor, ivabradine, and carvedilol on sinus node 4
[Ischemia with non-obstructive coronary artery disease: state-of-the-art review] 3
ACEF vs PARIS score in Predicting Cardiovascular Events in Patients With Acute Coronary Syndrome: Insights From the START ANTIPLATELET Registry 2
Totale 2.385
Categoria #
all - tutte 14.489
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.489


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 0 0 0 0 0 0 3 9 3 13 21 27
2020/2021113 3 12 8 9 5 20 4 8 10 2 19 13
2021/2022361 1 3 3 2 1 17 4 17 48 14 57 194
2022/2023511 80 32 23 14 58 36 7 31 65 124 24 17
2023/2024539 23 85 94 52 23 43 13 37 20 15 82 52
2024/2025467 138 114 14 43 71 87 0 0 0 0 0 0
Totale 2.385